The absence of comparative effectiveness data for hepatitis C (HCV) treatment in 2015 led to restricted treatment access as well as payer-mandated use of specific regimens. Patients with mild liver disease and those with recent alcohol/drug use were often excluded from treatment. Thus, key stakeholders had restricted choices about which patients would be approved to start treatment and which treatment would be approved while multiple direct-acting antiviral (DAA) regimens were available to treat HCV infection. A comparative effectiveness study was developed to understand if there were differences in the available treatments.
